Sun Pharma partners with ICGEB to develop dengue vaccine
pharmafile | October 19, 2016 | News story | Research and Development | Vaccine, dengue, icgeb, sun pharmaceutical
Indian drug firm Sun Pharma is set to join forces with the International Centre for Generic Engineering and Biotechnology (ICGEB) to develop a vaccine to tackle dengue and all four of its serotypes.
As part of the partnership, Sun Pharma will have exclusive global rights for the development and commercialisation of the vaccine candidate, and will provide support and funding to further the progress of ICGEB research and patents which include “a tailored recombinant virus-like particle (VLP) based tetravalent dengue vaccine”.
ICGEB has conducted pre-clinical studies over the past seven years and developed the existing knowhow and patents for this dengue vaccine candidate,” Sun Pharma commented. According to the company, the candidate induces serotype-specific non-cross-reactive and strongly neutralising antibodies without disease enhancing concerns. “These features of the candidate vaccine differentiate this vaccine development programme from other vaccine programmes that are developed or in development globally. This vaccine development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population,” the firm added.
On the other end of the agreement, ICGEB will disclose all pertinent research data in exchange for royalty and milestone payments for sales of the vaccine. The project will be overseen by a joint development committee formed from members of both organisations.
The pair previously announced a dengue-related collaboration in May 2016, focusing on a botanical drug treatment of the virus.
Matt Fellows
Related Content
GSK shares new data for RSV vaccine Arexvy
GSK announced positive results from its phase 3 trial which assessed the immune response and …
GSK and Zhifei partner for shingles vaccine promotion in China
GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological …
WHO recommends new vaccine for prevention of malaria in children
The World Health Organization (WHO) has announced that it has recommended a new vaccine, R21/Matrix-M, …
